Literature DB >> 1100088

A preliminary report on the effects of methanol extraction residue of BCG (MER) on cancer patients.

E Robinson, A Bartal, Y Cohen, R Haasz.   

Abstract

Twenty-seven patients with malignant neoplasia were injected intradermally with the methanol extraction residue (MER) fraction of tubercle bacilli. Two schedules of treatment were used: every other week and once a month; 1-10 courses of MER were administered to the patients. The skin reactivity to 3 recall antigens, as well as to the injected MER itself, was used to monitor the immune response. Improvement of skin reactivity occurred in 9 of 18 patients tested with recall antigens. Five of 6 patients treated every other week improved in their immune capacity whereas only 4 of 12 patients improved on the monthly schedule. Thus, repeated injections given every other week were more effective in increasing the cutaneous reactivity than monthly injections of MER. The side-effects of MER treatment were tolerable.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1100088      PMCID: PMC2024786          DOI: 10.1038/bjc.1975.126

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

1.  Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse.

Authors:  L J OLD; D A CLARKE; B BENACERRAF
Journal:  Nature       Date:  1959-07-25       Impact factor: 49.962

2.  BCG immunotherapy of rat tumors of defined immunogenicity.

Authors:  R W Baldwin; M V Pimm
Journal:  Natl Cancer Inst Monogr       Date:  1973-12

Review 3.  BCG and cancer.

Authors:  R C Bast; B Zbar; T Borsos; H J Rapp
Journal:  N Engl J Med       Date:  1974-06-27       Impact factor: 91.245

4.  Immunotherapeutic studies in mice with the methanol-extraction residue (mer) fraction of BCG: solid tumors.

Authors:  I Yron; D W Weiss; E Robinson; D Cohen; M G Adelberg; T Mekori; M Haber
Journal:  Natl Cancer Inst Monogr       Date:  1973-12

5.  Active immunotherapy for acute lymphoblastic leukaemia.

Authors:  G Mathé; J L Amiel; L Schwarzenberg; M Schneider; A Cattan; J R Schlumberger; M Hayat; F De Vassal
Journal:  Lancet       Date:  1969-04-05       Impact factor: 79.321

6.  Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin.

Authors:  J U Gutterman; G Mavligit; J A Gottlieb; M A Burgess; C E McBride; L Einhorn; E J Freireich; E M Hersh
Journal:  N Engl J Med       Date:  1974-09-19       Impact factor: 91.245

7.  Nonspecific stimulation and modulation of the immune response and of states of resistance by the methanol-extraction residue fraction of tubercle bacilli.

Authors:  D W Weiss
Journal:  Natl Cancer Inst Monogr       Date:  1972-12

8.  Facilitation of rat mammary tumour growth by BCG.

Authors:  W F Piessens; F L Lachapelle; N Legros; J C Heuson
Journal:  Nature       Date:  1970-12-19       Impact factor: 49.962

Review 9.  Immunological factors which influence response to immunotherapy in malignant melanoma.

Authors:  D Morton; F R Eilber; R A Malmgren; W C Wood
Journal:  Surgery       Date:  1970-07       Impact factor: 3.982

10.  Antituberculous immunity induced in mice by vaccination with killed tubercle bacilli or with a soluble bacillary extract.

Authors:  D W WEISS; R J DUBOS
Journal:  J Exp Med       Date:  1955-03-01       Impact factor: 14.307

View more
  3 in total

1.  Combined adjuvant therapy of radically operated colorectal cancer patients. (chemotherapy, radiotherapy, and MER-BCG).

Authors:  E Robinson; A Bartal; Y Cohen; N Haim; J Mohilever; T Mekori
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

2.  Granuloma formation in patients after injection of methanol extraction residue (MER-GCG).

Authors:  A Bartal; H Kerner; Y Cohen; E Robinson
Journal:  J Clin Pathol       Date:  1977-12       Impact factor: 3.411

3.  A preliminary study of intravenous methanol extraction residue of BCG in treatment of advanced cancer.

Authors:  E Robinson; A Bartal; J Honigman; Y Cohen
Journal:  Br J Cancer       Date:  1977-09       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.